TMEM196: A Potential Drug Target and Biomarker for Membrane Transporters

Target Name: TMEM196

NCBI ID: G256130

TMEM196

TMEM196: A Potential Drug Target and Biomarker for Membrane Transporters

Membrane transporters (MMs) are a diverse family of transmembrane proteins that play a crucial role in cellular signaling, ion transport, and other essential processes. They are involved in the transport of various molecules, including small molecules, ions, and signaling molecules across cell membranes. There are many different subfamilies of MMs, and each subfamily has its own unique structure and function. In this article, we will focus on TMEM196, a membrane transporter that is expressed in various tissues and cells and is involved in the transport of endogenous ligands.

TMEM196: Structure and Function

TMEM196 is a member of the Tmem196 family of transmembrane proteins. This family is characterized by the presence of a transmembrane domain, a cytoplasmic domain, and an N-terminus. TMEM196 has a unique structure, with a 196 amino acid long N-terminus that is rich in positively charged residues. This is indicative of its function as a potential drug target, as drugs that interact with negatively charged residues are more likely to interact with TMEM196 and potentially disrupt its function.

TMEM196 is expressed in various tissues and cells, including the brain, heart, liver, and pancreas. It is also highly expressed in the placenta, which suggests that it may be involved in fetal development and growth. TMEM196 is involved in the transport of several endogenous ligands, including hormone signaling molecules, growth factors, and neurotransmitters. This suggests that it may be a potential drug target for treating various diseases associated with hormone imbalances or neurotransmitter dysfunction.

TMEM196 is also involved in cellular signaling, as it is a component of several signaling pathways. For example, it is involved in the insulin/IGF-1 signaling pathway, which is involved in regulating glucose metabolism. Additionally, TMEM196 is involved in the TGF-β signaling pathway, which is involved in cell growth and differentiation. These involvement(s) in cellular signaling highlight TMEM196's potential as a drug target for diseases associated with insulin/IGF-1 or TGF-β signaling disruptions.

TMEM196 as a Biomarker

In addition to its potential as a drug target, TMEM196 may also be a useful biomarker for certain diseases. For example, TMEM196 has been used as a biomarker for pancreatic cancer, as its expression is often decreased in pancreatic cancer compared to normal tissue. This suggests that TMEM196 may be a potential diagnostic marker for pancreatic cancer. Additionally, TMEM196 has been used as a biomarker for other diseases, such as neurodegenerative diseases and autoimmune diseases.

Conclusion

In conclusion, TMEM196 is a membrane transporter that is involved in the transport of endogenous ligands and is expressed in various tissues and cells. Its unique structure and function, as well as its involvement in cellular signaling pathways, make it a potential drug target and biomarker for various diseases. Further research is needed to fully understand TMEM196's role in cellular signaling and its potential as a drug target and biomarker.

Protein Name: Transmembrane Protein 196

The "TMEM196 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM196 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets